Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
PrECOG, LLC.
Wake Forest University Health Sciences
Alliance for Clinical Trials in Oncology
Baptist Health South Florida
Shanghai Chest Hospital
Northwestern University
M.D. Anderson Cancer Center
University of Rochester
Second Affiliated Hospital of Nanchang University
Institut Bergonié
Guangzhou Medical University
University of Illinois at Chicago
NRG Oncology
University Health Network, Toronto
Intergroupe Francophone de Cancerologie Thoracique
Abramson Cancer Center at Penn Medicine
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Guangzhou Medical University
Guangzhou Medical University
Masonic Cancer Center, University of Minnesota
University of Alabama at Birmingham
University Hospital, Essen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fudan University
Memorial Sloan Kettering Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Gustave Roussy, Cancer Campus, Grand Paris
Peking University Cancer Hospital & Institute
Ohio State University Comprehensive Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Hyogo Medical University
Guangzhou Medical University
Guangzhou Medical University
Shanghai Chest Hospital
Guangzhou Medical University
Stanford University
Fox Chase Cancer Center
Goethe University
Sun Yat-sen University
Saint John's Cancer Institute
The First Affiliated Hospital of Guangzhou Medical University
Sichuan University
Sun Yat-sen University
Hunan Province Tumor Hospital
Vanderbilt-Ingram Cancer Center
Hunan Province Tumor Hospital
Shanghai Pulmonary Hospital, Shanghai, China